Although more than a dozen biosimilars have been approved by the FDA for use in the United States, three of which are indicated for use in cancer patients, many patients may be unfamiliar with the concept of biosimilars. A 2016 study of more than 3,000 individuals in the general population of the US and EU found that only 6 percent of the general population reported at least a general impression of biosimilars, with up to 70 percent reporting no knowledge of biosimilars at all¹.
When talking with your patients about prescribing biosimilars, there may be significant knowledge gaps in overall understanding, interchangeability and effectiveness. To help increase patient understanding and guide your conversations, Specialty Solutions Chief Medical Officer Chadi Nabhan, MD, and Sandeep Parsad, PharmD, BCOP, compiled a list of frequently asked questions in a JAMA Oncology patient reference guide. This guide features a basic overview of biosimilar products, their approval process and patient benefits, as well as information on how to address patient concerns.
Download the Guide